The Food and Drug Administration inspected Reproductive Medicine Associates of Southern California in Los Angeles on November 7, 2024. The inspection centered on the organization’s human cellular, tissue, and gene therapy practices, according to data posted on the FDA’s website.
The FDA’s final report concluded that Reproductive Medicine Associates of Southern California did not require any corrective actions regarding its operational management.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
